United Services Automobile Association Sage Therapeutics, Inc. Transaction History

United Services Automobile Association

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$140.29 - $189.96 $1.08 Million - $1.47 Million	-7,728 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$89.33 - $163.65 $47,166 - $86,407	528 Added 7.33%	7,728 $1.23 Million
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $19,419 - $33,111	-237 Reduced 3.19%	7,200 $690,000
Q3 2018 Nov 13, 2018	SELL	$138.11 - $169.04 $57,039 - $69,813	-413 Reduced 5.26%	7,437 $1.05 Million
Q2 2018 Sep 27, 2018	SELL	$140.36 - $175.76 $44.3 Million - $55.5 Million	-315,935 Reduced 97.58%	7,850 $1.23 Million
Q2 2018 Aug 10, 2018	BUY	$140.36 - $175.76 $44.4 Million - $55.7 Million	316,648 Added 4436.71%	323,785 $19 Million
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $1.09 Million - $1.37 Million	7,137 New	7,137 $1.15 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of United Services Automobile Association, based on Form 13F filings with the SEC.

Stay updated on United Services Automobile Association with notifications on news.